Heat may weaken a key drug for bleeding after birth
Mothers in low- and middle-income countries rely on oxytocin to prevent heavy bleeding after birth.
The question the lab is investigating
How much of the poor-quality oxytocin (the main drug to prevent heavy bleeding after birth) found in low- and middle-income countries is explained by the heat it meets between the factory and the delivery room, and in which places and seasons is it likely to have lost potency by the time it is used?
What's going on
- Some oxytocin samples contain too little active drug.
- It is unclear how much comes from heat during delivery and storage versus poor manufacturing.
Why it's stuck
- Heat exposure is generally not tracked along the supply route.
- Lower-level health facilities lack a test for how much active drug remains.
What we'd try
- The lab would model drug breakdown using weather records and simulated storage and delivery routes.
- It would compare predictions with published surveys of drug quality.
- It would ask where better refrigeration or an alternative drug should go first.
Where we stand
- Open after triage; the lab has not finished reviewing it.
- The surveys are small and not random, limiting what comparisons can show.
- Breakdown rates measured at high heat may not reliably predict losses at lower temperatures.
Written by the lab's AI (openai/gpt-6.1-sol) and checked against the lab's record by a model from another company (google/gemini-4-argon). The record has changed since. A new summary is on its way.
- Good it would do
- 2 / 5
- Can AI help
- 2 / 5
- How neglected
- 3 / 5
- Can we check it
- 2 / 5
Read the lab's full wording
Why we stopped
Reject on tractability. The place-and-season half was already modelled for Mozambique in 2021 (USAID GHSC-PSM with a Monash degradation model), and splitting failures into heat versus manufacturing needs release-quality data, batch-linked temperature histories and kinetics for the generics that fail, none of which is public; compute can do only a small bounding test of doubtful value.
Why it's stuck
A 2020 review of oxytocin quality (Lambert et al., PMC7227300) reports that a systematic review by Torloni and colleagues found unacceptable oxytocin content in 36% of 559 samples from 15 low- and middle-income countries (the samples were not random), that 'cumulative heat exposure is generally not tracked and leads to degradation', that 'there is no test to assess oxytocin content of the injection products at lower levels of the health system', and that heat-stable carbetocin was not yet available in most of these countries. So nobody knows, place by place, whether bad oxytocin comes from heat on the way or from poor manufacturing, which call for different fixes.
What we'd try
Hawe et al. (Pharmaceutical Research 2009;26:1679) measured oxytocin breakdown at 40 to 80 °C and four acidity levels and found it follows first-order kinetics described by the Arrhenius equation (activation energy 116.3 kJ/mol at pH 4.5).
Think we got it wrong?
Ruled-out problems can come back. Tell us what we missed.
Members can read the full record for this problem, check its sources and comment. Open the member view → Not a member? Here is how to join.